跳至主要内容
临床试验/NCT02238704
NCT02238704已完成不适用

A Cluster-randomized, Non-inferiority Open-label Trial of the Impact of Supplementation Regimen on Consumption of Prenatal Calcium and Iron/Folic Acid Supplements and Adherence to Related Recommendations

Cornell University16 个研究点 分布在 1 个国家目标入组 1,032 人开始时间: 2014年9月最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
1,032
试验地点
16
主要终点
Amount of calcium supplement ingested

研究概览

简要总结

The World Health Organization (WHO) now recommends prenatal calcium supplementation for prevention of preeclampsia in populations with inadequate dietary intake. This study seeks to compare the effect of two dosing strategies on the amount of supplement ingested by pregnant women and adherence to related recommendations.

详细描述

This study is a non-inferiority trial that compares the effect of a dosing strategy involving lower overall dose and fewer administrations per day to the current WHO recommendation. The comparator arm, Regimen B, prescribes 3 doses per day (consistent with current WHO standard) and was found to be burdensome in qualitative studies. The experimental arm, Regimen A, prescribes 2 doses per day and has been associated with greater satisfaction. On face value Regimen A should result in 33% less amount of supplement ingested than Regimen B. However, we hypothesize that the difference in amount ingested, when rolled out in routine practice will be MUCH LESS than that BECAUSE THE LOWER DOSE REGIMEN RESULTS IN HIGHER LEVELS OF ADHERENCE. We hypothesize that THE DIFFERENCE IN AMOUNT CONSUMED WILL BE NEGLIGIBLE OR will not exceed 15%. Hence, we hypothesize that Regimen A is not inferior to Regimen B in terms of total amount of supplement ingested (within a 15% margin of inferiority).

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Health Services Research
盲法
None

入排标准

年龄范围
15 Years 至 —(Child, Adult, Older Adult)
性别
Female
接受健康志愿者

入选标准

  • Attendance at ANC clinic in a primary care facility in Kakamega north

排除标准

  • Gestational age < 16 weeks,
  • Gestational age > 30 weeks,
  • Dietary or medicinal consumption of adequate calcium (according to the screening survey),
  • Intention to leave study community before 8weeks from date of interview

结局指标

主要结局

Amount of calcium supplement ingested

时间窗: 8 weeks after ANC consultation, during which recruitment into the study occurred

This is the actual number of supplements ingested expressed as a percentage of the number of supplements expected to be ingested since the ANC consultation if 100% adherent to the current WHO recommendation. \[Total number of calcium supplements consumed/(Number of days since last ANC consultation X 3)\] X 100

次要结局

  • Motivation(8 weeks after ANC consultation, during which recruitment into the study occurred)
  • Adherence to related recommendations(8 weeks after ANC consultation, during which recruitment into the study occurred)
  • Satisfaction(8 weeks after ANC consultation, during which recruitment into the study occurred)
  • Self-efficacy(8 weeks after ANC consultation, during which recruitment into the study occurred)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (16)

Loading locations...

相似试验

已完成
2 期
A randomized, open-label, parallel-group, multi-center study of adding edoxaban or clopidogrel to aspirin to maintain patency in subjects with peripheral arterial disease following femoropopliteal endovascular intervention-edoxaban in peripheral arterial disease (ePAD)narrowing of the peripheral arteries (mostly in the legs)periferal arterial disease10003216
NL-OMON40071Daiichi Sankyo Development Ltd14
已完成
1 期
A Trial of TAS-114 in Combination With S-1Advanced Solid Tumors
NCT02454062Taiho Oncology, Inc.120
已完成
2 期
A multi-centre, open-label, single-arm, dose-finding phase I/II study to evaluate safety, tolerability, dosing schedule, and preliminary efficacy of carrier-added 4-L-[131I]iodo-phenylalanine (131I-IPA), administered as single or repetitive injections in patients with recurrent glioblastoma multiforme (GBM), concomitantly to 2nd line external radiation therapy (XRT) - IPAX-1StudyBrain cancerGMB10029211
NL-OMON49405TELIX International Pty Ltd2
进行中(未招募)
1 期
Research study aiming at investigating the potential safety and clinical activity of multiple administrations of NKR-2 in patients with different metastatic tumor types. The treatment is based on patient's own T-cells that will be collected and modified before being injected to generate anti-tumor responses.
EUCTR2016-003312-12-BECelyad SA122
已完成
不适用
A phase I, open-label, multi-center, dose escalation study of oral BGJ398, a pan FGF-R kinase inhibitor, in adult patients with advanced solid malignanciesAdvanced and/or metastatic cancer10027655
NL-OMON45230ovartis13